Decitabine (DAC)1. In vivo;2. Mainly evaluated the efficacy when combined with anti-PD1 therapy;3. Combined therapy inhibited tumor growth;4. CD8+ TILs resisted exhaustion and maintained greater expansion potential;. This evidence concerns the gene CD8A and neoplasm.